Humasis
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Humasis is listed on KOSDAQ and classified under Health Care, Pharmaceuticals. Its market value is US$48.1M. In FY2025 it reported revenue of US$22.7M and an operating loss of US$8M.
A written company profile is not available yet; the facts above come from exchange and DART data.
Humasis in five facts
Where is Humasis listed and in which sector?
Humasis (Korean name: 휴마시스) trades under KRX code 205470 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Humasis?
Its market capitalisation was US$48.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Humasis's latest annual revenue and operating profit?
For fiscal year 2025, Humasis reported revenue of US$22.7M, an operating loss of US$8M and a net loss of US$16.4M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 18.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Resolution to convene a general shareholders' meeting (extraordinary meeting)Oct 21
- Proxy solicitation reference documentOct 21
- Notice of general shareholders' meetingOct 21
- [Amended] Resolution to convene a general shareholders' meeting (extraordinary meeting)Oct 14
- [Amended] Resolution to convene a general shareholders' meeting (extraordinary meeting)Sep 15
- Report on securities held by executives/major shareholdersSep 11
- Report on large shareholdings (5% rule) (standard)Sep 11
- Report on large shareholdings (5% rule) (standard)Sep 4
- Report on securities held by executives/major shareholdersSep 4
- Change of largest shareholderOwnership change · May 18
- Trading suspension (share consolidation/split registration)M&A · Apr 9
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Humasis reported consolidated results for FY2025: revenue of US$20.6M (+18.4% year on year), an operating loss of US$7.24M and a net loss of US$14.1M.
Earnings · Feb 10